The compound of the formula ##STR00001## wherein the * indicates an
asymmetric carbon, is specific to alpha.sub.2B adrenergic receptors in
preference over alpha.sub.2A and alpha.sub.2C adrenergic receptors, and
as such has no or only minimal cardivascular and/or sedatory activity.
The compound is useful as medicament in mammals, including humans, for
treatment of diseases and or alleviations of conditions which are
responsive to treatment by agonists of alpha.sub.2B adrenergic receptors.